头孢哌酮-舒巴坦治疗革兰阴性杆菌感染慢性支气管炎患者效果评价  

Comprehensive evaluation of Cefoperazone-Sulbactam in treatment of chronic bronchitis of gram-negative bacteria infection

作　　者：崔跃[1] 

机构地区：[1]沈阳市第五人民医院呼吸内科,辽宁110023

出　　处：《社区医学杂志》2015年第20期18-19,共2页Journal Of Community Medicine

摘　　要：目的分析头孢哌酮-舒巴坦治疗革兰阴性杆菌感染慢性支气管炎患者的临床效果。方法选择72例慢性支气管炎合并革兰阴性杆菌感染的患者,按照随机数字表法分为观察组和对照组各36例。观察组给予头孢哌酮/舒巴坦治疗,对照组给予头孢他啶治疗,观察两组患者的临床疗效、细菌清除率及不良反应情况。计数资料采用χ2检验,P<0.05为差异有统计学意义。结果观察组患者的临床疗效为94.45%,对照组为77.78%,观察组明显优于对照组,差异有统计学意义(P<0.05);观察组患者细菌清除率(91.67%)明显高于对照组(72.22%),差异有统计学意义(P<0.05)。结论头孢哌酮-舒巴坦治疗革兰阴性杆菌感染慢性支气管炎临床疗效可靠,细菌清除率高,且无明显的副作用,值得临床上使用。Objective To analyze the clinical efficacy of Cefoperazone- Sulbactam in treatment of chronic bronchitis of gram- negative bacteria infection. Methods 72 patients with chronic bronchitis of gram- negative bacteria infection were randomly divided into observation group and control group. Patients in the observation group（ n = 36） were treated with Cefoperazone- Sulbactam,while patients in the control group（ n = 36） were given ceftazidime. The clinical efficacy and adverse reactions in the two groups were observed. Count data was used by chi square test,P〈0. 05 was considered statistically significant. Results The effective rate was 94. 45% in the observation group and 77. 78% in the control group,with significant differences between the two groups（ P〈0. 05）. The bacterial eradication rate in the observation group（ 91. 67%） was significantly higher than that in the control group（ 72. 22%）（ P〈0. 05）. Conclusions Cefoperazone- sulbactam in treatment of chronic bronchitis of gram- negative bacteria infection was proved to be a safe and effective therapy,worthy of further clinical application.

关 键 词：慢性支气管炎 革兰阴性杆菌 头孢哌酮-舒巴坦 头孢他啶 

分 类 号：R562.21[医药卫生—呼吸系统]